Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. more
Time Frame | KTTA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.69% | -1.66% | 0.16% |
1-Month Return | -7.58% | -3.08% | 1% |
3-Month Return | -28.24% | -6.66% | 10.69% |
6-Month Return | -45.54% | -1.54% | 12.9% |
1-Year Return | -65.5% | 8.85% | 30.94% |
3-Year Return | -94.09% | 7.9% | 29.66% |
5-Year Return | -95.72% | 45.12% | 92.82% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | 15.06K | 486.56K | 486.56K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":3.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Cost of Revenue | - | 17.27K | 113.19K | 648.45K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":2.66,"profit":true},{"date":"2022-12-31","value":17.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | - | (2.21K) | 373.36K | (648.45K) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.59,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-173.68,"profit":false}] | |
Gross Margin | - | (14.69%) | 76.74% | (133.27%) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-19.15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-173.68,"profit":false}] | |
Operating Expenses | 40.98K | 4.51M | 15.19M | 15.98M | [{"date":"2020-12-31","value":0.26,"profit":true},{"date":"2021-12-31","value":28.19,"profit":true},{"date":"2022-12-31","value":95.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (40.98K) | (4.51M) | (14.82M) | (15.98M) | [{"date":"2020-12-31","value":-4098000,"profit":false},{"date":"2021-12-31","value":-450741300,"profit":false},{"date":"2022-12-31","value":-1481632100,"profit":false},{"date":"2023-12-31","value":-1597936100,"profit":false}] | |
Total Non-Operating Income/Expense | - | 2.33M | 860.98K | 714.05K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":36.9,"profit":true},{"date":"2023-12-31","value":30.6,"profit":true}] | |
Pre-Tax Income | (40.98K) | (2.17M) | (13.94M) | (15.51M) | [{"date":"2020-12-31","value":-4098400,"profit":false},{"date":"2021-12-31","value":-217352100,"profit":false},{"date":"2022-12-31","value":-1393645200,"profit":false},{"date":"2023-12-31","value":-1550774800,"profit":false}] | |
Income Taxes | (61.48K) | 508.00 | (879.97K) | 453.91M | [{"date":"2020-12-31","value":-0.01,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-0.19,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |
Income After Taxes | - | (2.17M) | (13.06M) | (469.42M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-217402900,"profit":false},{"date":"2022-12-31","value":-1305648100,"profit":false},{"date":"2023-12-31","value":-46941774800,"profit":false}] | |
Income From Continuous Operations | - | (2.17M) | (13.94M) | (16.74M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-217352100,"profit":false},{"date":"2022-12-31","value":-1393645200,"profit":false},{"date":"2023-12-31","value":-1673845500,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (40.98K) | (2.17M) | (13.06M) | (15.96M) | [{"date":"2020-12-31","value":-4098400,"profit":false},{"date":"2021-12-31","value":-217402900,"profit":false},{"date":"2022-12-31","value":-1305648100,"profit":false},{"date":"2023-12-31","value":-1596165800,"profit":false}] | |
EPS (Diluted) | (0.07) | (0.14) | (0.53) | (5.30) | [{"date":"2020-12-31","value":-7.1,"profit":false},{"date":"2021-12-31","value":-13.81,"profit":false},{"date":"2022-12-31","value":-53,"profit":false},{"date":"2023-12-31","value":-530.42,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
KTTA | |
---|---|
Cash Ratio | 14.18 |
Current Ratio | 14.81 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KTTA | |
---|---|
ROA (LTM) | -37.90% |
ROE (LTM) | -63.25% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KTTA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 44.21 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.96 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KTTA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 42.15 |
P/B | 0.20 |
Price/FCF | NM |
EV/R | 277.44 |
EV/Ebitda | 2.90 |
Pasithea Therapeutics Corp (KTTA) share price today is $3.03
Yes, Indians can buy shares of Pasithea Therapeutics Corp (KTTA) on Vested. To buy Pasithea Therapeutics Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KTTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Pasithea Therapeutics Corp (KTTA) via the Vested app. You can start investing in Pasithea Therapeutics Corp (KTTA) with a minimum investment of $1.
You can invest in shares of Pasithea Therapeutics Corp (KTTA) via Vested in three simple steps:
The 52-week high price of Pasithea Therapeutics Corp (KTTA) is $9.6. The 52-week low price of Pasithea Therapeutics Corp (KTTA) is $2.8.
The price-to-earnings (P/E) ratio of Pasithea Therapeutics Corp (KTTA) is
The price-to-book (P/B) ratio of Pasithea Therapeutics Corp (KTTA) is 0.20
The dividend yield of Pasithea Therapeutics Corp (KTTA) is 0.00%
The market capitalization of Pasithea Therapeutics Corp (KTTA) is $3.60M
The stock symbol (or ticker) of Pasithea Therapeutics Corp is KTTA